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ABSTRACT 
Objective: The purpose of this study was to evaluate the LOX inhibitory activity, and predict the drug likeness properties of designed diacyl 
derivatives of phloroglucinol, using in silico method.  
Methods: The designed derivatives were subjected to molecular docking using AUTODOCK while the receptor used in this study was built from 
SWISS MODEL. Drug likeness properties of the derivatives were calculated by online programs i.e. MOLINSPIRATION and PreADMET.  
Results: Molecular docking study revealed that designed tHGA derivative with four-carbon chain length exhibited the best binding affinity with the 
docking scores of -7.26kcal/mol. Three types of binding interactions were observed between the derivatives and the receptor site i.e H-bonding, 
hydrophobic and Van der Waals interactions. The important amino acid residues involved in H-bonding were Gln495 and Gln697, while other amino 
acid residues, such as Leu754 and Ile 553, were involved in the Van der Waals interaction. The designed tHGA derivatives were mainly stabilized 
through hydrophobic interactions with His499, His504, Ile538, Phe557 and Val750. In silico physicochemical calculations predicted that all the designed 
derivatives passed the Lipinski’s Rule of 5, and have good human intestinal absorption property (HIA>70%). Further, all the designed derivatives 
showed moderate central nervous system absorption (0.6<BBB<2.0), except for the derivative with a longer (5-Cs) chain length.  
Conclusion: The findings of the present study suggested that changing the acyl and geranyl side chains of the natural product molecule, tHGA, into 
two acyl bearing side chains, will improve its pharmacodynamic and pharmacokinetic profiles.  
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INTRODUCTION 
Asthma is a chronic disease characterized by recurrent attacks of 
breathlessness and wheezing, which differ in severity and frequency 
among different individuals [1]. Human 5-lipoxygenase (5-LO) plays 
a crucial role in pathogenesis of asthma through the metabolism of 
arachidonic acid (AA) at the 5-position which leads to the formation 
of 5-hydroperoxyeicosatetraenoic acid (5-HPETE). 5-HPETE is then 
converted into leukotrienes LTA4 which is then enzymatically 
metabolized to LTB4, LTC4, LTD4, and LTE4. The lipid mediators 
cysteinyl leukotrienes (CysLTs) including LTC4, LTD4, and LTE4
Meanwhile, the human 15-LOX-1 enzyme converts arachidonic acid 
(AA) and linoleic acid into 15(S)-HPETE and 13(S)-
hydroperoxyoctadecadienoic acid (13(S)-HPODE) which 
subsequently undergo reduction and transformation into 15(S)-
hydroxyeicosatetraenoic acid (15(S)-HETE) and 13(S)-
hydroxyoctadecadienoic acid (13(S)-HODE). Both 15(S)-HETE and 
13(S)-HODE metabolites cause epithelial injury in the airway, 
resulting in asthma [5].  
 are 
the major source of potent proinflammatory mediators that bind to 
H protein-coupled receptors (GPCRs), contributing to allergic 
disorders, such as asthma [2-4].  
Plant LOX is also involved in the oxygenation of linoleic acid to 
generate 13-HODE [6]. Therefore, drug design strategies targeting 
the inhibition of the key enzyme that responsible for biosynthesis of 
pro-inflammatory metabolites mentioned earlier, are crucial for 
treating asthma. Nevertheless, soybean LOX (15sLOX) has been used 
as an alternative biological screen, replacing human LOX, due to 
difficulties in obtaining purified human LOX and the highly 
conserved catalytic domain of both isoenzymes [7-9].  
The natural product molecule 2,4,6-trihydroxy-3-geranyl 
acetophenone (tHGA), isolated from Melicope ptelefolia has been 
reported to inhibit the synthesis of cysteinyl leukotrienes (CysLTs) in 
activated macrophages through 5-LOX inhibition [10]. Previous animal 
study by Ismail et al., (2012) also confirmed the effectiveness of tHGA 
as a potential lead compound in preventing allergic airway 
inflammation [11]. Following this, a series of tHGA analogues were 
designed and synthesized by Ng et al., (2014), by employing Friedel-
Craft acylation and alkylation reactions. They further investigated the 
structure-activity relationship of the analogues, based on the soybean 
15-LOX enzyme inhibitory activity, where the analogues were shown 
to exhibit potent, dose-dependent activity, with IC50 value of 10.31-27.61 
µM. The most active tHGA analogue exhibited 2-fold higher 15-LOX 
inhibitory activity than tHGA (IC50 
METHODS 
= 23.61 µM). The findings strongly 
suggested that elongation of the acyl-bearing aliphatic chain (2Cs-5Cs) 
and presence of the aromatic moiety, greatly enhanced the enzyme 
inhibition in comparison to the unmodified structure of tHGA. However, 
increase the chain length of the molecules is expected to reduce 
solubility, and, therefore, will also indirectly affect the bioavailability of 
the compound [12, 13]. Thus, in-sillico studies are important to give a 
better insight into the structure-activity relationship (SAR) of designed 
molecules, in order to justify the full picture of the pharmacophore. 
Therefore, this study aimed to investigate the potential LOX inhibition 
property and predict the drug likeness properties of several designed 
derivatives using in silico method.  
Preparation of protein and ligand molecules  
Homology model of soybean LOX-1, built using SWISS MODEL, was 
retrieved from our previous study [13] and used in the present work. 
Chem Draw Ultra 12.0 was used to construct 3-dimensional 
structures of the target compounds [14]. The chemical structures of 
tHGA and the most active tHGA analogue were obtained from a 
previous study [12], while the designed tHGA derivatives (1-4) are 
shown in fig. 1. 
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Fig. 1: Chemical structures for designed derivatives, tHGA and its most active analogue 
 
Molecular docking 
Docking study was applied to the modelled soybean LOX-1 receptor 
using Autodock tool (ADT) software. The protein needs to be pre-
treated before docking by getting rid of water and co-crystallized 
inhibitors, excluding the cofactor iron (Fe3+
Prediction of drug likeness properties  
). The Autodock tool was 
used to assign Gasteiger charges, adding missing hydrogen atoms, 
and non-polar hydrogen atoms were merged. The molecular docking 
calculations were carried out on the active site of the modelled 
soybean LOX-1. The grid box (24.958 x-0.033 x 19.021Å and 100 x 
100 x 100Å dimensions) were centered on the co-crystallized 
inhibitor. The Lamarckian Genetic Algorithm (LGA) was employed 
and a total of 100 calculations were performed. All other parameters 
were set at their default values. The binding affinity of the 
derivatives was evaluated through interpolated energy calculations 
(calculated free energy of binding). The best docked ligands were 
quantified through scoring function. The analysis of the binding 
interaction was examined through Discovery Studio (DS) Viewer 
software.  
Nine descriptors were calculated through Molinspiration online 
database (www. molinspiration. com), including molecular formula, 
molecular weight, LogP, polar surface area, number of O or N atom, 
number of OH or NH atom, number of rotatable bonds, volume, and 
number of violations to Lipinski’s rule, for all selected compounds 
[15, 16].  
The Pre-ADMET program was accessed at http://preadmet.bmdrc.org/. 
The chemical structures of selected compounds were drawn and 
analyzed automatically by the program. The program automatically 
calculates predictive plasma protein binding (PPB), blood brain barrier 
(BBB) permeability, human intestinal absorption, permeability for Caco-
2-cell, MDCK cell, and skin permeability values [17].  
RESULTS 
Molecular docking  
The four designed diacyl derivatives (1-4) of tHGA, along with tHGA 
and the previously reported most active analogue were subjected to 
molecular docking onto the active LOX receptor site, using Autodock. 
The molecular docking energy of the target compounds are tabulated 
in table 1. Derivative 2 showed the highest docking score (-7.26 
kcal/mol), followed by tHGA (-6.76 kcal/mol), tHGA analogue (-6.71 
kcal/mol), derivative 4 (-6.68 kcal/mol), derivative 1 (-6.37 kcal/mol) 
and derivative 3 with (-6.26 kcal/mol). Derivative 3 has the lowest 
docking score among all four diacyl derivatives. This could be due to 
the bulkier acyl side chain, which causes more stearic hindrance, even 
though the binding pattern is similar to tHGA[18]. The molecular 
binding model of diacyl derivatives (1-4), tHGA and tHGA analogue in 
the active site of LOX-1 homology model are shown in fig. 2-7. 
  
 
(a)  (b) 
Fig. 2: Molecular binding model of derivative 2 in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D diagram. In (a), green 
line indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions, purple line indicates π-sigma 
interactions. In (b), the atoms are colored gray for carbon, red for oxygen, blue for nitrogen, and light grey for hydrogen; amino acid 
residues are indicated in red color word 
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Table 1: Molecular docking energy of diacyl derivatives (1-4), tHGA and most active tHGA analogue 






tHGA analogue -6.71 
 
 
(a)  (b) 
Fig. 3: Molecular binding model of derivative 4 in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D diagram. In (a), green 
line indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions, red line indicates unfavorable 
donor-donor interactions. In (b), the atoms are colored gray for carbon, red for oxygen, blue for nitrogen, and light grey for hydrogen; 






Fig. 4: Molecular binding model of derivative 1 in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D diagram. In (a), green 
line indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions, purple line indicates π-sigma 
interactions. In (b), the atoms are colored gray for carbon, red for oxygen, blue for nitrogen, and light grey for hydrogen; amino acid 
residues are indicated in red color word 
 
 
(a)  (b) 
Fig. 5: Molecular binding model of derivative 3 in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D diagram. In (a), green 
line indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions. In (b), the atoms are colored gray 
for carbon, red for oxygen, blue for nitrogen, and light grey for hydrogen; amino acid residues are indicated in red color word 
Chean et al. 







Fig. 6: Molecular binding model of tHGA in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D diagram. In (a), green line 
indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions, orange line indicates π-anion 
interaction, red line indicates unfavorable hydrogen donor-donor interaction. In (b), the atoms are colored gray for carbon, red for 






Fig. 7: Molecular binding model of the most potent tHGA analogue in the active site of LOX-1 homology model: (a) 2D diagram; (b) 3D 
diagram. In (a), green line indicates hydrogen-bonding interactions, light purple line indicates alkyl and π-alkyl interactions. In (b), the 
atoms are colored gray for carbon, red for oxygen, blue for nitrogen, and light grey for hydrogen; amino acid residues are indicated in red 
color word 
 
Prediction of drug likeness properties 
Lipinski’s rule of 5 states that a chemical or drug compound is more 
likely to be a potential drug for human use if it fulfills the following 
criteria i. e log P value of no more than 5, number of hydrogen bond 
acceptors (nON) of no more than 10, number of hydrogen bond 
donors (nOHNH) of no more than 5 and molecular weight of no 
more than 500, number of rotatable bonds of no more than 10 and 
polar surface area (PSA) of no more than 140Å [19]. Commonly, the 
number of violations for an oral drug does not exceed one under the 
given criteria of Lipinski’s rule of 5 [19]. The drug likeness and 
molecular properties of the target compounds in the present study 
were calculated by using Molinspiration cheminformatics software. 
The values are shown in table 2. Meanwhile, the prediction ADMET 
results for all the tested compounds are shown in table 3. Caco-2 
permeability, MDCK permeability, HIA and SKlogP values were 
calculated based on in vitro models used to assess the intestinal 
absorption of a compound [20]. 
 









nONb nOHNHd nrotbe Volume f No. 
Violation 
In silico % 
ABSa 
1 C12H14O 238.24 5 2.28 94.83 5 3 4 212.79 0 76.28365 
2 C14H18O 266.29 5 3.40 94.83 5 3 6 246.39 0 76.28365 
3 C14H18O 266.29 5 2.77 94.83 5 3 4 245.96 0 76.28365 
4 C16H22O 294.35 5 4.41 94.83 5 3 8 280.00 0 76.28365 
tHGA C19H24O 304.39 4 5.08* 77.75 4 3 6 307.31 1 88.07 
tHGA 
analogues 
C20H27O 346.47 4 6.64* 77.75 4 3 9 348.97 1 88.07 
aIn silico % ABS was calculated by equation: 109-[0.345 x TPSA], bTPSA: Topological polar surface area, cMi Log P: Logarithm of compound partition 
coefficient between n-octanol and water, dnON: number of hydrogen bond acceptor, enOHNH: number of hydrogen bond donor, f
 
nrotb: number of 
rotatable bonds, *did not meet the criteria of Lipinski’s rule of 5 
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Caco-2 (nm/sec) c MDCKd Skin permeability (nm/sec) 
1 C12H14O 93.376 5 0.624 75.286 20.588 60.789 -3.874 
2 C14H18O 99.724 5 1.260 79.472 2.181 41.486 -3.267 
3 C14H18O 100.000 5 1.27175 79.429 20.735 45.807 -3.270 
4 C16H22O 100.000 5 2.392 82.840 10.444 9.739 -2.621 
tHGA C19H24O 100.000 4 2.145 88.415 12.891 0.247 -2.040 
tHGA 
analogue 
C20H27O 100.000 4 5.8597 89.88 14.4797 0.285 -1.559 
aPPB: Plasma protein binding, bBBB: Blood brain barrier, cHIA: Human intestinal absorption, d
 
MDCK: Madin-Darby canine kidney 
DISCUSSION 
Docking results showed that the hydroxyl group on the phloroglucinol 
moiety of derivative 2 (fig. 2) formed 2 important hydrogen bonds 
with the surrounding amino acid residues Gln495 (O–H—O–H) and 
Gln697 (O–H—O–H) with a distance of 1.96 Å and 1.94 Å, respectively. 
The benzene ring of the phloroglucinol moiety, formed a π–sigma 
bond with Ile553 with a distance of 3.92 Å, and interacts with Leu 754 
through π–alkyl interaction, with a distance of 3.92 Å. Both the acyl 
side chains on the benzene ring were also stabilized through 
hydrophobic interactions with His504 (3.91 Å), His 499 (4.48 Å), 
Ile538 (5.42 Å), Phe557 (4.69 Å), Ile751 (4.83 Å), and Val750 (4.14 Å). 
Similarly, the hydroxyl group on the benzene ring of derivative 4 (fig. 
3) also formed 1.88 Å and 2.00 Å hydrogen bonds (O–H—O–H) with 
the same amino residues, Gln495 and Gln697. An unfavorable 
binding interaction detected between the hydroxyl group on the 
benzene ring and the nitrogen atom of Trp500 (O–H—N–H) with a 
distance of 2.56 Å. The terminal end of the acyl chain formed van der 
Waals force with an amino residue, Ile553 (H–C—C–H) with a 
distance of 5.26 Å. Derivative 4 has comparative binding energy with 
the most active tHGA analogue (table 1). Derivative 4 has shorter 
side chains, consisting of two 5-Cs acyl side chains, while the latter 
consisted of one 5-Cs acyl group and one geranyl group. Derivatives 
2 and 4 have hydrophobic interaction with the same amino acid 
residues, His504 (4.43 Å), His499 (5.38 Å), Ile538 (4.96 Å), Phe557 
(4.74 Å) and Val750 (8.95 Å). Other residues involved in 
hydrophobic binding were Ala542 (4.06 Å), Leu546 (4.52 Å) and 
Ile552 (5.10 Å).  
As with derivatives 2 and 4, the hydroxyl group on the 
phloroglucinol moiety of derivative 1 (fig. 4) was stabilized through 
hydrogen bonding with amino residues Gln697 (O–H—O–C), with 
distance of 2.04 Å and with Gln495 (O–H—O–C), with distance of 
2.03 Å. Similar to derivative 2, π–π (H–C—C–H), with distance of 
5.47 Å, and π–alkyl (H–C—C–H), with distance of 5.06 Å, bonding 
interactions were observed between the benzene ring of derivative 
1 with the amino acid residues Leu754 and Ile 553. The terminal end 
of the acyl chains also formed hydrophobic clusters with the 
residues Phe557 (4.94 Å), Ile751 (4.78 Å), Val750 (3.89 Å), His504 
(4.02 Å), Ile538 (5.49 Å) and His499 (4.54 Å).  
Derivative 3 (fig. 5) showed relatively different binding interactions, 
in comparison to all the other compounds. This could be due to its 
bulkier acyl side chain, which leads to more stearic hindrance and an 
altered binding affinity [23]. The hydroxyl group on the benzene 
ring of derivative 3 formed important hydrogen bondings with 
amino acid residues Gln579 (O–H—O–C), Asp584 (O–H—O–C) and 
Tyr493 (O–H—O–C), with distances of 2.06 Å, 2.04 Å and 1.93 Å, 
respectively. The carbonyl group of the acyl side chains also showed 
hydrogen binding interactions with residues Asn502 (C–O—H–N), 
with distance of 3.05 Å, and Gln 579 (C–O—H–N), with distance of 
2.79 Å. The alkyl group on the acyl side chains interact with residue 
Trp574 (H–C—C–H) through π–alkyl bonding, with a distance of 
4.42 Å. The amino acid residues involved in the hydrophobic binding 
interaction with the terminal end of the acyl side chains of derivative 
3 included Leu689 (4.80 Å), Leu501 (5.23 Å) and Val570 (4.69 Å). 
Binding interactions observed for tHGA (fig. 6) and the most active 
tHGA analogue (fig. 7) were very similar. For example, both 
compounds are stabilized through similar hydrophobic binding 
interactions with amino acid residues Val570 and Trp574. 
Furthermore, the hydroxyl and acyl groups of both compounds 
showed hydrogen bondings with amino acid residues Asp584 and 
Cys357. On the other hand, tHGA formed unfavorable bonding 
interaction, with a distance of 2.69 Å, between the hydroxyl group 
on phloroglucinol moiety with the amino acid residue Asp588 (O–
H—H–N). 
In terms of molecular properties calculation, the molecular weights 
of all target compounds are within the limits of Lipinski rule (MW≤ 
500Da). This revealed that the diacyl derivatives, tHGA and tHGA 
analogue, have favorable permeability through cellular membranes. 
Meanwhile, all the diacyl derivatives (1-4) have LogP values of no 
more than 5, which were also within the limits of Lipinski’s rule. The 
decreased LogP values of the diacyl derivatives (1-4), as compared 
to tHGA and tHGA analogue, indicated that acylation improved 
aqueous solubility, which enabled the drug to transfers across 
membrane and be absorbed easily [21]. The low-aqueous solubility 
of prenylated acylphloroglucinols, due to significant lipophilicity, 
based on in silico study, have also been reported by Ilieve et al., 
(2018). Structural simplification, elimination of problematic 
functionalities, and decreased lipophilicity are important drug 
design strategies to improve the pharmacokinetic properties of the 
drug [22]. A mere reduction of 1 unit for LogP value is equivalent to 
a 10-fold increase in drug solubility [23]. Thus, it can be concluded 
that tHGA derivatives (1-4) can exhibit 10 to 30-fold increase in 
solubility, based on the predicted value. The LogP values of the 
diacyl derivatives (1-4) increased as the chain length of the acyl 
group increase; the LOX inhibitory activity increased throughout the 
series up to a maximum, corresponding to derivative 2 (4-C length; -
7.26kcal/mol) and decreased to derivatives 4 (5-C length; -
6.68kcal/mol) followed by derivative 1 (3-C length; -6.37kcal/mol) 
and derivative 3 (4-C length with bulkier branched structure; -
6.26kcal/mol).  
The intermolecular interactions of a drug with water molecules can 
be altered by the number of hydrogen bond donors and acceptor 
groups within a molecular structure. With higher number of 
hydrogen bonds, it is more thermodynamically unfavorable for a 
drug to diffuse into a lipid environment, which means that it is more 
difficult for drug to transport across cellular membrane. As a result, 
the number of hydrogen bond groups is restricted in the Lipinski 
Rule of 5 [24, 25]. The number of hydrogen bond donors (nOHNH) 
and number of hydrogen bond acceptors (nON) in tHGA compound, 
analogue and diacyl derivatives (1-4) obeyed the Lipinski’s rule of 5.  
The flexibility of the drug molecules, determined by the number of 
rotatable bonds within the drug structure, is used to determine the 
binding affinity of drug molecules with the receptor site. A flexible 
drug has a higher binding affinity compared to a less flexible drug [26]. 
All the target compounds evaluated in the present study have number 
of rotatable bonds which were in accordance with the Lipinski’s rule 
i.e. less than 10. Therefore, all of the compounds are predicted to be 
orally active, in compliance with Lipinski’s rule of 5 [27].  
Topological polar surface area (TPSA) can be used to indicate the 
bioavailability of a drug compound as it is well correlated with the 
hydrogen bonding of the molecule. The TPSA values of tHGA and 
tHGA analogue were 77.75Å, while the four diacyl derivatives were 
the same, i. e 94.83Å, all of which did not exceed the limit of 160 Å. 
The percentage absorption values for the designed derivatives were 
76.28%, while for tHGA and tHGA analogue were 88.07%. Generally, 
Chean et al. 
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a compound is indicated as having good oral bioavailability if its 
percentage absorption ranged between 74.03% to 105.65%. Based 
on the values shown by the target compounds, it was therefore 
predicted that all the compounds possess good oral bioavailability.  
All the compounds also have Caco-2 permeability values ranging 
from 10 to 20, except for derivative 2, indicating that they have 
moderate absorption in the human body (table 3). The low Caco-2 
permeability value of 2.181 of derivative 2 suggested that the 
derivative possess low absorption potential. Based on MDCK values, 
drug permeability can be classified into three levels, i.e. low (<25); 
medium (25-500) and high (>500). Derivatives 1, 2 and 3 have 
medium permeability, while derivative 4, tHGA compound and tHGA 
analogue have low permeability. Overall, the diacyl derivatives (1-4) 
showed better absorption than tHGA and tHGA analogue. 
The skin permeability (Kp) values for all the target compounds were 
negative (table 3). This indicated that they permeate the skin poorly 
[28]. These compounds were designed to be taken orally, therefore 
their Kp values should be low so that any accidental contact would 
not result in drug absorption. Human intestinal absorption (HIA) of 
a drug candidate is an essential property to evaluate for a potential 
drug candidate as it has significant influence over both 
bioavailability and absorption properties of the drug [29]. As shown 
in table 3, all the target compounds have HIA% values of more than 
70%. Thus, the compounds are predicted to be well absorbed by the 
human intestine.  
The percentage of plasma protein binding (PBB) is a critical 
pharmacokinetics factor in determining the optimum dosage regimen 
or frequency of administration [30]. All the tHGA derivatives 
presented more than 90% PPB value, which indicated that they are 
strongly bound to plasma protein. Therefore, higher dosages of the 
compounds could be applied. Blood-brain barrier (BBB) permeability 
is essential for drug molecules to be active in the central nervous 
system. As shown in table 3, except for derivative 4, all the designed 
derivatives exhibited moderate CNS absorption values. Similar to 
derivative 4, both tHGA and tHGA analogue exhibited high CNS 
absorption, thus they have unfavorable BBB properties.  
CONCLUSION 
The ligand-receptor binding interactions of diacyl derivatives of the 
natural product compound, tHGA, were studied through molecular 
docking. Derivative 2 showed promising LOX inhibitory activity, as 
indicated by its highest ligand-receptor interaction energies (-
7.76kcal/mol). The presence of two acyl bearing groups result in a 
better pharmacokinetic profile, as shown by the in silico drug-like 
properties, predicted through Molinspiration and ADME profiling 
using PreADMET. The present study suggested that these tHGA 
derivatives could be promising compounds for further development 
into potent LOX inhibitors, which warrants further in vitro and in 
vivo investigations to confirm their pharmacokinetics and 
pharmacodynamics profiles.  
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